Summit Therapeutics (SMMT) Stock Hits 52-Week Low After FDA Rejects Lung Cancer Drug
Summit Therapeutics’ SMMT shares fell about 17% to near $11.70 after the FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer, citing insufficient overall survival proof. Jefferies sees limited downside; Barclays cut its target to $18.
How this was made

The 30-second read
Why it matters
The regulatory denial directly caused a 17% pre‑market decline, pushing the stock to a 52‑week low and prompting analysts to cut price targets.
Market read
The FDA denial is a primary catalyst for Summit's stock, creating immediate trading opportunity and broader biotech sector implications.
What to watch
Potential partnership with Akeso and upcoming HARMONi‑3 data could mitigate the impact if results are compelling.
Background
Summit Therapeutics announced an FDA Complete Response Letter for its ivonescimab trial in EGFR‑mutated NSCLC, citing insufficient overall‑survival benefit.
Ticker impact
FDA issued a Complete Response Letter rejecting ivonescimab, sending Summit Therapeutics shares down ~17% to a new 52‑week low.
likely further downside as investors price in the regulatory setback
Regulatory denial is a material catalyst for biotech stocks; the stock already fell 17% pre‑market and may continue to sell off on the news.
Market effects
Biotech sector may see heightened scrutiny on lung‑cancer programs, pressuring peers with similar trials.
U.S. biotech stocks could face short‑term pressure; limited impact outside North America.
Regulatory outcomes in the U.S. often set precedent for global approvals, modestly affecting global biotech sentiment.
Counterpoint
If Summit can generate additional data to meet the OS endpoint, the stock may rebound on a future resubmission.
Key entities
- companySummit Therapeutics Inc.
Biopharma developing ivonescimab for lung cancer.
- regulatorFDA
U.S. Food and Drug Administration issuing the rejection.
- partnerAkeso
Collaborator on Summit's Phase III studies.




